 |
 |
|
St. Jude Medical Acquires Radi Medical Systems
Date: December 22, 2008
Client: Radi Medical Systems
|
|
|
|
 |
|
S*BIO Enters Research Collaboration with Tan Tock Seng Hospital for Therapeutic and Biomarker Evaluation of JAK2 Inhibitor SB1518
Date: December 19, 2008
Client: S*BIO
|
|
|
|
 |
|
Targanta Announces Corporate Restructuring
Date: December 18, 2008
Client: Targanta Therapeutics
|
|
|
|
 |
|
Date: December 17, 2008
Client: OmegaGenesis
Summary: OmegaGenesis and the Mayo Clinic are collaborating for the discovery and validation of nano-materials used for angiogenesis applications.
|
|
|
|
 |
|
Helix BioPharma Reports on 2008 Annual General Meeting and Provides Corporate Update
Date: December 16, 2008
Client: Helix BioPharma
|
|
|
|
 |
|
"OmegaGenesis and Mayo Clinic form R&D collaboration"
Date: December 16, 2008
Client: OmegaGenesis
Summary: OmegaGenesis, a venture funded bio-technology company, has entered into a collaboration with Mayo Clinic, a non-profit medical practice, for the discovery and validation of nano-materials used for angiogenesis applications. At Mayo Clinic, researchers have produced one of the rare earth materials in nano size and established non-toxicity of the material for human applications and have shown the material induces endothelial cell growth and produces new blood vessels. OmegaGenesis is developing applications based on these unique characteristics of nano materials for proactive maintenance of the human body.
|
|
|
|
|
|
Date: December 16, 2008
Client: OmegaGenesis
Summary: OmegaGenesis has developed methods to safely generate large-scale quantities of nanoscale europium hydroxide rods, which were first developed at the Mayo Clinic and have been shown to promote angiogenesis.
|
|
|
|
 |
|
"OmegaGenesis to Leverage Mayo Clinic's Nanomaterial Research in Angiogenesis Applications"
Date: December 16, 2008
Client: OmegaGenesis
Summary: OmegaGenesis and Mayo Clinic have decided to work together to discover and validate nanomaterials in angiogenesis applications. The deal includes licenses for Mayo Clinic technology and patents as well as a research collaboration.
|
|
|
|
 |
|
"EntreMed Focuses on Development of ENMD-2076"
Date: December 15, 2008
Client: EntreMed
|
|
|
|
 |
|
"OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications"
Date: December 15, 2008
Client: OmegaGenesis
|
|
|
|
|
|
"OmegaGenesis Announces Angiogenesis Application Collaboration"
Date: December 15, 2008
Client: OmegaGenesis
|
|
|
|
 |
|
"Molecular Insight considering partnership for Zemiva due to current economy, executive says; data release imminent" - Beth Herskovits
Date: December 12, 2008
Client: Molecular Insight Pharmaceuticals
Summary: Molecular Insight, the listed Massachusetts-based biopharmaceutical company, is considering a partnership for its most advanced compound Zemiva - even though it had previously planned to commercialize the imaging agent itself, said John Babich, president.
|
|
|
|
 |
|
"Alfacell Announces Management Update"
Date: December 12, 2008
Client: Alfacell
|
|
|
|
|
|
"Helix BioPharma Announces Q1 2009 Financial Results"
Date: December 11, 2008
Client: Helix BioPharma
|
|
|
|
 |
|
"Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans"
Date: December 11, 2008
Client: Vical
|
|
|
|
|
|
"Alfacell Reports Financial Results for First Quarter of Fiscal 2009"
Date: December 10, 2008
Client: Alfacell
|
|
|
|
|
|
"Alfacell's ONCONASE® and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells"
Date: December 10, 2008
Client: Alfacell
|
|
|
|
|
|
"SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial"
Date: December 9, 2008
Client: Vical
|
|
|
|
|
|
"EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma"
Date: December 9, 2008
Client: EntreMed
|
|
|
|
|
|
"FDA Issues Complete Response Letter for Oritavancin"
Date: December 8, 2008
Client: Targanta Therapeutics
|
|
|
|
|
|
"Alfacell Provides ONCONASE® NDA Submission Update"
Date: December 5, 2008
Client: Alfacell
|
|
|
|
 |
|
"Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer "
Date: December 5, 2008
Client: Taligen Therapeutics
|
|
|
|
 |
|
"Pairing a bioengineered stent with a drug-eluting balloon could solve two problems" - Chris Kaiser
Date: December 4, 2008
Client: OrbusNeich
Summary: The Genous Bio-engineered R stent, which captures a patient's endothelial progenitor cells to accelerate the natural healing process, has been shown to reduce late and very late thrombosis compared with drug-eluting stents (DES). The Genous stent, however, has not bested its DES counterparts in reducing in-stent restenosis. A trial in development that will use a drug-eluting balloon to dilate the artery, in combination with deployment of the Genous stent, hopes to fill in the gaps.
|
|
|
|
|
|
"Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey"
Date: December 3, 2008
Client: Vical
|
|
|
|
 |
|
"febit appoints Jack Leonard, Ph.D., Vice President of Technology Commercialization"
Date: December 2, 2008
Client: febit
|
|
|
|
|
|
"S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis"
Date: December 2, 2008
Client: S*BIO
|
|
|
|
|
|
"S*BIO Pte Ltd., of Singapore, said it started a Phase I/II trial of SB1518, an oral JAK2 inhibitor, in patients with chronic idiopathic myelofibrosis."
Date: December 2, 2008
Client: S*BIO
|
|
|
|
 |
|
"Llew Keltner - Battling solid tumours with light"
Date: December 1, 2008
Client: Light Sciences Oncology
Summary: Pharmaceutical Technology Europe interviews Llew Keltner, President, CEO and Director of Light Science Oncology (WA, USA). The company has developed a promising new cancer treatment that uses light-emitting diodes to activate a drug inside solid tumours.
|
|
|
|
|
|
"Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial"
Date: December 1, 2008
Client: Vical
|
|
|
|
 |
|
"ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection"
Date: December 1, 2008
Client: Anadys Pharmaceuticals
|
